AZN vs JNJ
AstraZeneca PLC and Johnson & Johnson, both Healthcare
Johnson & Johnson is the larger company at $550B against $288B. On trailing earnings AZN is the cheaper of the two at a P/E of 26.2 against 30.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year JNJ returned +53% against +5.4% for AZN. The RyuScore puts JNJ ahead, 69 against 60 out of 100.
| Figure | AZN | JNJ |
|---|---|---|
| Last close | $159 | $261 |
| Market cap | $288B | $550B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 26.2 | 30.3 |
| Dividend yield | n/a | 2.0% |
| 1-year return | +5.4% | +53% |
| 5-year return | +57% | +80% |
| RyuScoresector-relative, 1–10 | 60/100 | 69/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AstraZeneca PLC
Revenue of $31B in H2 2025, net income $4.9B.
Johnson & Johnson
Revenue of $25B in Q2 2026, net income $5.5B. Its largest reported line is DARZALEX, 19% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.